Alveavax-v1.2
- Generic Name
- Alveavax-v1.2
Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention
Phase 1
Completed
- Conditions
- Sars-CoV-2 Infection
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Alvea Holdings, LLC
- Target Recruit Count
- 130
- Registration Number
- NCT05844202
- Locations
- 🇿🇦
JOSHA Research, Bloemfontein, Free State, South Africa
🇿🇦MERC Research Pty Ltd, Middelburg, Mpumalanga, South Africa
🇿🇦NMMM Pharmmedica Health and Clinical Research, Johannesburg, Gauteng, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath